| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Common stock repurchase | 2,706 | 2,565 |
| Net cash provided by financing activities | 10,888 | 8,578 |
| Net increase in cash and cash equivalents | -689 | 411 |
| Effect of exchange rate changes on cash | -1,949 | - |
| Cash and cash equivalents at beginning of period | 19,533 | - |
| Cash and cash equivalents at end of period | 16,895 | - |
Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc. (ALLR)